An EpiPen For Heart Attacks? Idorsia Launches Phase III Study Of Selatogrel

Rapid-Onset Anti-Platelet Drug Shows Promise

 
• By Andrew McConaghie
  
Idorsia building
Idorsia is anticipating US FDA approval of its first candidate, insomnia drug daridorexant in 2022, with selatogrel among several late-stage assets. • Source: Idorsia

More from Clinical Trials

More from R&D